Benralizumab (Fasenra) has been listed on the PBS from 1 December for the treatment of uncontrolled severe eosinophilic asthma. The listing will provide subsidised access for around 670 patients to the monoclonal antibody-based subcutaneous injections, which would otherwise cost up to $21,000 a year. Benralizumab joins two other biologics that are PBS-listed for severe asthma, ...
Already a member?
Enter your email to keep reading.